Marlies Carbo

Marlies Carbo

Auto-generated profile, based on publicly available information

Marlies Carbo

Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
MCMarlies Jg Carbo
Marlies Jg Carbo
DPDavy Paap
Davy Paap
FMFiona Maas
Fiona Maas
ABAnna Jetske Baron
Anna Jetske Baron
LOLaura C van Overbeeke
Laura C van Overbeeke
ASAnneke Spoorenberg
Anneke Spoorenberg
Aim: Adaptation of the Short QUestionnaire to Assess Health-enhancing physical activity (SQUASH) in order to improve measurement properties in axSpA patients. Methods: The original SQUASH was adapted using a qualitative stepwise approach with in-depth interviews including healthcare professionals and patients. Content validity was explored by comparing modified-SQUASH (mSQUASH) and original SQUASH. Next, mSQUASH was validated according to the OMERACT filter. International Physical Activity Questionnaire (IPAQ) was used as comparator and tri-axial accelerometer as gold standard for criterion validity and classification accuracy of intensity. Construct validity was assessed using Spearman correlations with clinical outcome assessments. For test-retest reliability, intra-class correlation coefficients (ICCs) were calculated. Responsiveness was assessed using standardized response mean (SRM), stratified by Anchor method. Results: The mSQUASH measured a systematically higher activity count and had less missing values (8% vs. 16%) then SQUASH. mSQUASH correlated better with accelerometer compared to IPAQ (rho = 0.60 vs. rho = 0.34). Accelerometer measured most activity in light intensity, whereas mSQUASH and IPAQ predominately measured moderate intensity. Correlations with ASDAS, BASDAI, BASFI and ASQoL were better for mSQUASH then IPAQ. Test-retest reliability was good in both questionnaires. In contrast to IPAQ responsiveness was in correspondence with self-reported changes in physical activity for mSQUASH (SRM -0.84 for improvement and 0.88 for decrease). The average completion time of the mSQUASH was 7 minutes. Conclusions: The development of the mSQUASH resulted in an easy applicable, valid, reliable and responsive questionnaire for the assessment of daily physical activity in axSpA patients, which can be used in research and daily clinical practice. (C) 2021 The Authors. Published by Elsevier Inc.

24 April 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMarlies J G Carbo
Marlies J G Carbo
ASAnneke Spoorenberg
Anneke Spoorenberg
FMFiona Maas
Fiona Maas
EBElisabeth Brouwer
Elisabeth Brouwer
RBReinhard Bos
Reinhard Bos
SASuzanne Arends
Suzanne Arends
Non-steroidal anti-inflammatory drugs (NSAIDs) are regarded as the cornerstone of conventional treatment for AS. However little is known about concomitant NSAID use during treatment (with TNF-α inhibitors) in daily clinical practice. Consecutive patients from the GLAS cohort were included. NSAID use and ASAS-NSAID index were evaluated at group level and at individual patient level during 52 weeks of follow-up. Analyses were stratified for treatment regimen. Generalized estimating equations (GEE) was used to evaluate NSAID use in relation to assessments of disease activity over time. In patients starting TNF-α inhibitors (n = 254), 79% used NSAIDs at baseline and this proportion decreased significantly to 38% at 52 weeks. ASAS-NSAID index also decreased significantly from median 65 to 0. In patients on conventional treatment (n = 139), 74% used NSAIDs at baseline with median ASAS-NSAID index of 50 and this remained stable during follow-up. At each follow-up visit, approximately half of the patients changed their type or dose of NSAIDs. GEE analysis over time showed that NSAID use was associated with AS disease activity score (p<0.05). This relation was more pronounced in patients treated with TNF-α inhibitors compared to conventional treatment (B = 0.825 vs. B = 0.250). In this observational cohort of established AS patients, there was no difference in baseline NSAID use between patients with and without indication for TNF-α inhibitors. NSAID use decreased significantly after starting TNF-α inhibitors. During conventional treatment, NSAID use remained stable at group level. However, NSAID use changed frequently at individual patient level and was significantly associated with disease activity.

17 May 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMarlies Carbo
Marlies Carbo
DPDavy Paap
Davy Paap
LOLaura van Overbeeke
Laura van Overbeeke
FWFreke Wink
Freke Wink
HBHendrika Bootsma
Hendrika Bootsma
ASAnneke Spoorenberg
Anneke Spoorenberg
Objective: To evaluate daily physical activity (PA) in relation to psychosocial factors, such as anxiety, depression and different types of coping strategies, as well as patient- and disease-related factors in patients with axial spondyloarthritis (axSpA). Methods: Consecutive outpatients from the Groningen Leeuwarden AxSpA (GLAS) cohort completed the modified Short Questionnaire to assess health-enhancing PA (mSQUASH), Hospital Anxiety and Depression Scale (HADS) and Coping with Rheumatic Stressors (CORS) questionnaires, as well as standardized patient- and disease-related assessments. Univariable and multivariable linear regression analyses and comparison of lowest and highest PA tertiles were performed to explore associations between the HADS, CORS, patient- and disease-related factors and PA. Results: In total, 84 axSpA patients were included; 60% male, mean age 49 (SD ±14) years, median symptom duration 20 (25th-75th percentiles: 12–31) years, mean ASDAS 2.1 (±1.0). Higher PA levels were significantly associated with better scores on patient-reported disease activity (BASDAI), physical function (BASFI) and quality of life (ASQoL). Furthermore, higher levels of PA were associated with less impact of axSpA on wellbeing and lower HADS depression scores. In the multivariable linear regression model, less use of the coping strategy ‘decreasing activities’ (β: -376.4; p 0.003) and lower BMI (β:-235.5; p: 0.030) were independently associated with higher level of PA. Comparison of patients from the lowest and highest PA tertiles showed results similar to those found in the regression analyses. Conclusion: In this cohort of axSpA patients, higher levels of daily PA were associated with better patient-reported outcomes and lower depression scores. Additionally, the passive coping strategy “decreasing activities” and lifestyle factor BMI were independently associated with PA. Besides anti-inflammatory treatment, coping strategies and lifestyle should be taken into account in the management of individual axSpA patients. Incorporating these aspects into patient education could increase patient awareness and self-efficacy. In the future, longitudinal studies are needed to better understand the complex relationship between patient-, disease- and psychosocial factors associated with daily PA.

23 October 2024 in RMD Open
Verified
Journal Article
Open access
PDF file
YKYvonne M van der Kraan
Yvonne M van der Kraan
LGLianne Gensler
Lianne Gensler
DPDavy Paap
Davy Paap
ETEllen Thovmasyan
Ellen Thovmasyan
NANoa Ausma
Noa Ausma
SASuzanne Arends
Suzanne Arends
Background The modified Short QUestionnaire to ASsess Health-enhancing physical activity (mSQUASH) was originally developed and validated in Dutch patients with axial spondyloarthritis (axSpA). To support world-wide distribution, applicability and comparability of measuring physical activity, our aim was to perform translation and cross-cultural adaptation of the mSQUASH into English, field testing in other rheumatic diseases and clinical validation in patients with axSpA. Methods The Dutch mSQUASH was translated into English according to forward–backward Beaton protocol. Semistructured interviews were conducted in representative samples of patients with axSpA (n=13), Sjögren’s disease (n=10), systemic lupus erythematosus (n=10) and giant cell arteritis/polymyalgia rheumatica (n=10) to verify relevance, comprehensiveness and comprehensibility. For construct validity (n=95), Spearman correlations were used with clinical outcome assessments. For test–retest reliability (n=82), intraclass correlation coefficients (ICC) were calculated. For responsiveness (n=80), standardised response means (SRM) were calculated stratified by Anchor method. Results Translation and cross-cultural adaptation of the mSQUASH into English were successfully carried out, which can serve as basis for other translations. Only minor adaptations and clarifications were implemented. Fair correlations were found between mSQUASH and Axial Spondyloarthritis Disease Activity Score (ρ=−0.31), Bath Ankylosing Spondylitis Functional Index (ρ=−0.37) and Assessment of SpondyloArthritis International Society-Health Index (ρ=−0.30). Test–retest reliability was very good (ICC: 0.87). Responsiveness corresponded to the direction of self-reported changes in physical activity (SRM: 0.72 for improved, 0.06 for stable and −0.74 for worsened). Conclusion The mSQUASH showed good linguistic and face validity according to field testing in different rheumatic diseases. Clinical validation confirmed good construct validity, test–retest reliability and responsiveness in patients with axSpA, which supports the use of the mSQUASH in clinical practice and research.

5 January 2024 in Arthritis Care & Research
Verified
Journal Article
Open access
AKAnne Kampman
Anne Kampman
FWFreke Wink
Freke Wink
DPDavy Paap
Davy Paap
MCMarlies Carbo
Marlies Carbo
MSMark Siderius
Mark Siderius
SASuzanne Arends
Suzanne Arends
Objective: The objective of this study was to explore to what extent patients with axial spondyloarthritis (axSpA) link experienced pain in the neck, back, and hips to inflammation and/or structural damage.Methods: Patients from the Groningen Leeuwarden Axial Spondyloarthritis (GLAS) cohort visiting the outpatient clinic between 2016 and 2019 filled out two additional questions in relation to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) question 2: (1) “To what extent do you think the pain you experience in your neck, back, and hips is related to inflammation caused by axSpA?” and (2) “To what extent do you think the pain you experience in your neck, back, and hips is related to damage of the spine and joints caused by axSpA?” Answers had to be depicted on a numeric rating scale from 0 (none) to 10 (very much); a difference of ≥2 points between the scores of these questions was considered clinically relevant in favor of the highest scoring question.Results: A total of 688 patients with axSpA (24% with nonradiographic axSpA [nr‐axSpA]) were included (62% male, mean ± SD age 48 ± 14 years, and mean ± SD Ankylosing Spondylitis Disease Activity Score [ASDAS] 2.3 ± 1.0). Seventy‐five percent of patients could not link the origin of their pain, 15% linked axial pain predominantly to inflammation, and 10% linked axial pain predominantly to damage. Patients in the inflammation group were younger, had shorter symptom duration, were more frequently diagnosed with nr‐axSpA, had higher ASDASCRP, had more often elevated CRP levels, had fewer comorbidities, had better spinal mobility, and had less spinal radiographic damage.Conclusion: In our large observational cohort, the majority of patients with axSpA could not differentiate the origin of experienced axial pain. If patients were able to link axial pain to clinical inflammation or damage, it was in concordance with clinical assessments and radiographic outcome, which may be helpful in establishing the origin of pain and supporting better patient‐centered treatment decisions.